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Introduction: Five nucleos(t)ide analogs are used to treat chronic hepatitis B. Ideal nucleos(t)ide analog therapy in
chronic hepatitis B patients with kidney transplantation must ensure virological suppression and minimize renal
injury. However, resistance to nucleos(t)ide analogs frequently results in virological breakthrough, hepatitis flare, and
complicated deterioration of the transplanted kidney. Inappropriate rescue therapy for drug resistance may
subsequently cause hepatitis B virus multidrug resistance. Currently, tenofovir is used to treat chronic hepatitis B
patients with kidney transplantation. In the field, we first reported combination therapy with tenofovir plus
entecavir in a kidney transplant chronic hepatitis B patient with nucleos(t)ide analog multidrug resistance.
Case presentation: A 50-year-old Chinese man with chronic hepatitis B and kidney transplantation received
nucleos(t)ide analog therapy with sequential monotherapy and combination therapy. Virological parameters, hepatic
enzymology and renal function were monitored. Drug-resistance mutations were detected by sequence analysis.
Our patient received sequential nucleos(t)ide analog monotherapy and inappropriate combination therapy during
132 months, which caused multidrug resistance and renal functional injury. Entecavir plus adefovir was administered
in month 106, resulting in decreased hepatitis B virus load, normal hepatic function, and stabilized creatinine
clearance. As a result of rebounded viral load and significantly declining creatinine clearance, tenofovir plus
entecavir was administered in month 133. After eight weeks, undetectable hepatitis B virus DNA, normal hepatic
function and improved creatinine clearance were present. Compared with combination therapy with adefovir plus
entecavir, tenofovir plus entecavir showed a potent antiviral effect for multidrug resistance and minimized renal injury.
Conclusions: In chronic hepatitis B patients with kidney transplantation, sequential monotherapy with antiviral agents
with low barriers to resistance should be avoided, and initial therapy with entecavir is a better option. Combination
therapy with tenofovir plus entecavir in this setting with multidrug resistance is safe and effective.
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Approximately 350 to 400 million people worldwide are
chronically infected with hepatitis B virus (HBV) [1,2]. As a
result of viral replication and the host immune response,
these patients may develop progressive chronic hepatitis B
(CHB). Drugs for treating CHB include interferon (IFN)
and nucleos(t)ide analogs (NAs). The advantages of IFN are
the absence of resistance and the potential for immune-
mediated control of HBV infection, but its disadvantages* Correspondence: njwp7810@163.com
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unless otherwise stated.include severe side effects, contraindication in female pa-
tients during pregnancy, and aggravating illness in patients
with decompensated cirrhosis or autoimmune disease. In
particular, IFN should be avoided in patients with organ
transplantation because of the risk of acute rejection [1,3].
Therefore, CHB patients with kidney transplantation
should simultaneously receive immunosuppressive agents
and NAs, instead of IFN.
NAs can be classified into nucleosides (lamivudine,
telbivudine, emtricitabine and entecavir) and nucleotides
(adefovir and tenofovir). Five NAs, namely lamivudine,
adefovir, entecavir, telbivudine and tenofovir, are currently
approved worldwide for CHB treatment [1,2]. In China,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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infection before 2005, adefovir, entecavir and telbivudine
were approved for CHB treatment between 2005 and
2007 [4], and tenofovir was used to treat HBV resistance
in 2012. As a result of cost constraints, prescription
regulations, or both, a considerable proportion of
physicians in China still start monotherapy with NAs
that are low barriers to resistance, including lamivudine,
adefovir and telbivudine. These inadequate therapies
may induce HBV resistance, or even multidrug resist-
ance. At present, combination therapy is recommended
for CHB with resistant mutations. An ideal combination
therapy should include drugs with different mechanisms
of action, such as a combination of entecavir plus adefovir
or entecavir plus tenofovir [2].
Kidney transplantation is the best treatment for end-
stage kidney disease. HBV infection in kidney transplant
recipients still constitutes a major problem because CHB
flare is a significant cause of mortality after transplantation.
Compared with IFN, NAs are currently more efficient and
safe for treating CHB after kidney transplantation.
However, multiple factors limit NA administration,
including the risk of kidney injury, the low barrier to re-
sistance, and cross-resistance mutation in different NAs
[2,5,6]. Infectious disease physicians do not understand
fully the basic principles of resistance or management
strategies of kidney injury in this setting, therefore, in-
adequate NA therapy can increase the risk of kidney in-
jury, develop multidrug resistance, and even result in
progressive liver disease.
Here we present a CHB patient with kidney transplan-
tation who developed viral breakthrough, multidrug resis-
tance, and complicated renal function decline during NA
treatment. Finally, combination therapy with tenofovir
plus entecavir resulted in undetectable HBV load and
improvement of renal function.
Case presentation
A 50-year-old Chinese man underwent kidney transplan-
tation for chronic renal failure and complicated CHB.
He suffered glomerulonephritis complicating renal failure
without detectable HBV markers and underwent
hemodialysis for two years. Finally, kidney trans-
plantation was performed. Immunosuppression and
anti-rejection therapy, namely mycophenolatemofetil,
tacrolimus and prednisolone, were routinely adminis-
tered after kidney transplantation. As a result of the
side effects of tacrolimus, he developed the postoperative
complication of type 2 diabetes mellitus, and insulin was
administered to control hyperglycemia. On hemodialysis,
he was positive for hepatitis B surface antigen, hepatitis B e
antigen (HBeAg), hepatitis B core antibody and HBV DNA
(CobasAmplicor, Roche Diagnostics, Basel, Switzerland;
low limit of quantification: 60IU/ml) with normal liverenzymes and was diagnosed with asymptomatic HBV
infection. At age 39 years, he had active hepatitis B with
elevated alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) but normal creatinine clearance
(CC). Monotherapy with lamivudine 100mg daily was im-
mediately administered, and this time point was identified
as month 1 (Figure 1). Before 2005, monotherapy with
lamivudine was the only choice. After 51 months, viro-
logical breakthrough and hepatitis flare were detected, and
lamivudine resistance was detected by sequence analysis
(Applied Biosystems 3500 Series Genetic Analyzer; Life
Technologies, Carlsbad, CA, USA). A series of monother-
apies was performed, namely adefovir 10mg daily for eight
months, telbivudine 600mg daily for eight months, and
entecavir 1.0mg daily for 17 months. Unfortunately, in-
creased HBV load (103 to 104IU/ml), positive HBeAg and
fluctuating ALT values within three times the upper limit f
normal (ULN) were shown during the three years.
Sequential monotherapy resulted in virological break-
through, resistance mutation, and partial virological
response, hence combination therapies were chosen.
An inappropriate regimen, lamivudine 100mg plus
entecavir 1mg daily, was administered in month 87, in
an attempt to inhibit HBV and avoid continuous renal
damage. Following this therapy, viral load decreased to
100IU/ml after two months, but rebounded to 2.6×103IU/
ml in month 104. Resistance mutations with rtL180M and
rtM204V were again detectable. Renal function showed that
serum creatinine levels were at ULN, and CC was
59.5ml/min. Tenofovir had not yet been approved in
China by 2011.
Therefore alternative therapy with entecavir 1mg plus
adefovir 10mg daily was applied to inhibit viral load in
month 106. Three months later, this treatment decreased
viral load to 130IU/ml, and maintained stable CC, fluctuat-
ing between 59.5 and 73.6ml/min. In month 114, viral load
was 80IU/ml (low limit of quantification: 20IU/ml), and CC
58.5ml/min. However, in month 133, viral load rebounded
to 480IU/ml, CC decreased to 50.5ml/min, and multidrug
resistance mutations, namely rtL180M, rtM204V, rtA181T
30%/V 20%/wt 50% and rt T184G 40%/wt 60%, were iden-
tified by sequence analysis (Applied Biosystems 3500 Series
Genetic Analyzer and Pyrosequencing PSQ 96MA;Life
Technologies). Combination treatment with entecavir
0.5mg plus tenofovir 300mg daily was immediately
selected in month 133. Viral load and serum creatinine
gradually decreased, and CC correspondingly increased.
Four months later, treatment with entecavir plus tenofovir
resulted in undetectable HBV DNA with <20IU/ml, nor-
mal ALT and AST, and CC 76.5ml/min (Figures 1 and 2).
Discussion
Ideal NA therapy in CHB patients with kidney transplan-
tation must ensure virological suppression with undetectable
Figure 1 Alanine aminotransferase and creatinine clearance levels during nucleos(t)ide analog therapy. Because various physicians in
various hospitals have separately participated in nucleos(t)ide analog therapy in different phases, parameters of liver enzymes, renal function and
DNA load from month 1 to month 60 have not been recorded. Fluctuating alanine amino transferase levels showed during nucleos(t)ide analog
therapy. Two bottom of creatinine clearance were present in month 104 and in month 133. The box showed the nucleos(t)ide analog-resistant
mutations by sequence analysis. LVD, lamivudine; ETV, entecavir; ADV, adefovir; LdT, telbivudine; TDF, tenofovir; wt,wild-type.
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the progression of liver disease and maintain anti-
rejection therapy after kidney transplantation. However,
resistance to NAs frequently results in virological break-
through, acute exacerbation of liver disease, and com-
plicated deterioration of the transplanted kidney. The
emergence of drug resistance and the subsequent need for
rescue therapy increases the risk of developing HBV
multidrug resistance. In this report, a CHB patient with
kidney transplantation received sequential monotherapy
with NAs and inappropriate combination therapies, which
caused multidrug resistance and renal functional injury.
An alternative combination therapy with entecavir plus
adefovir was administered in month 106. As a result of
rebounded HBV load and significantly declining CC,
combination therapy with tenofovir plus entecavir was ad-
ministered in month 133. After eight weeks, undetectable
HBV DNA, normal hepatic function, and improvement of
CC were present. Compared with combination therapy
with adefovir plus entecavir, tenofovir plus entecavir
shows a potent antiviral effect for multidrug resistanceand minimized renal injury in patients with kidney
transplantation.
All NAs are cleared by the kidneys and dose adjust-
ments are recommended according to the patient’s CC,
as listed in the drug information. Because tenofovir had
not yet been approved in China by 2011, we alternatively
chose combination therapy with entecavir plus adefovir
in month 106, in an attempt to inhibit HBV replication
and maintain stable CC. If CC was <50ml/min, adefovir
dosage would be simultaneously regulated according to
the drug information for adefovir. However, our patient’s
CC was >50ml/min during the entire period of therapy,
therefore adefovir dosage was not adjusted. Combination
therapy with entecavir 1mg plus adefovir resulted in low
viral load and generally normal CC during 28 months.
Unfortunately, this combination therapy did not com-
pletely inhibit HBV replication, and eventually induced
viral rebound and renal function decline.
Entecavir and tenofovir, as potent HBV inhibitors with
a high barrier to resistance, are recommended as first-
line monotherapy for CHB patients [1,2]. However,
Figure 2 Hepatitis B virus DNA and hepatitis B e antigen levels during nucleos(t)ide analog therapy. Viral load rebound presented in
month 104 and in month 133. Combination therapy with entecavir 1mg plus adefovir 10mg daily was applied to inhibit viral load in month 106.
Multidrug resistance mutations, namely rtL180M, rtM204V, rtA181T 30%/V 20%/wt 50% and rt T184G 40%/wt 60%, were identified in month 133.
Thus, combination treatment with entecavir 0.5mg plus tenofovir 300mg daily was immediately selected in this time point. Viral load gradually
decreased, and creatinine clearance correspondingly increased.
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vudine resistance, and thus tenofovir may be a better op-
tion in patients with lamivudine resistance, including
those with kidney transplantation [5]. For patients with
multidrug resistance, tenofovir plus entecavir may be
preferred [2]. Thus, tenofovir plus entecavir was admi-
nistered to inhibit multidrug resistance in the present
case, and induced a rapid decrease in HBV DNA and
HBeAg and improvement of renal function during four
months (Figures 1 and 2).
Currently, tenofovir is used to treat CHB patients with
kidney transplantation or chronic kidney disease, such as
in the investigation of Daudé and case report of Das in
2011 [6,7]. Tenofovir treatment showed excellent
efficacy in inhibiting HBV and in maintaining renal func-
tion. Recently, Pipili has suggested that tenofovir is a
better option in kidney transplant patients with drug
resistance [5]. In our report, tenofovir treatment of a
CHB patient with kidney transplantation was also safe
and efficacious, consistent with the previous results. In
addition, the case report of Das showed that a patientwith nephrotic syndrome and HBV infection was treated
by tenofovir plus lamivudine, resulting in arrest of pro-
teinuria and stabilization of renal function [7]. The data
of Das were similar to our present report, in that teno-
fovir inhibited HBV and improved renal function,
simultaneously.
Side effects of tenofovir are mainly proximal tubular
injury namely Fanconi’s syndrome, isolated hypopho-
sphatemia, and decreased bone mineral density [8].
Some authors have reported that 15% of patients with
tenofovir treatment lasting two to nine years developed
renal tubular dysfunction associated with acute or
chronic kidney injury, but this illness might be reversible
[9-11]. In a multicenter, prospective cohort study, only
small nonprogressive decreases in renal function were
observed in 3% of patients with tenofovir treatment last-
ing five years [12]. Therefore, renal function, electrolytes,
and bone mineral density should be periodically detected
in long-term therapy with tenofovir.
In addition, we discussed the inadequate or mistaken
NAs therapies in this case, including: (1) adefovir
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quential monotherapy with lamivudine, adefovir, telbivu-
dine and entecavir and (3) combination therapy with
lamivudine plus entecavir or pegylated IFN plus enteca-
vir. Currently, many authors have suggested that sequen-
tial monotherapy with antiviral agents with low barriers
and hence high or intermediate risk of resistance (lami-
vudine, adefovir and telbivudine) should be strictly
avoided, because of the increasing risk of multidrug
resistance [2]. In patients with monodrug resistance,
appropriate rescue therapy should add an effective anti-
viral agent that does not share cross-resistance to com-
bination therapy. For lamivudine resistance, combination
therapy with lamivudine plus adefovir is an option [2,4].
However, the rescue therapy for lamivudine resistance in
the present case in month 51 was switching to adefovir,
instead of adding it. Subsequently, a series of sequential
monotherapies and mistaken combination therapies
caused multidrug resistance. As a result of the shared re-
sistance mutations between telbivudine and lamivudine,
monotherapy with telbivudine in months 60 to 68 was
mistaken. The incorrect combination therapy with lami-
vudine and entecavir in months 87 to 102 also contri-
buted to the multidrug resistance. Even some infectious
disease physicians have proposed combination therapy
with pegylated IFN plus entecavir to treat multidrug
resistance in month 105. This mistaken therapeutic
strategy has doubtless been rejected by renal physicians.
Two factors have led to the above regimens. First, physi-
cians in various hospitals, including those for infectious
disease and renal disease, and our own hospital, have
separately participated in NA therapy in different phases,
but not all physicians understand the basic principles of
resistance, pharmacokinetics of NAs, and management
strategies for kidney transplantation. Therefore, no
systematic rescue therapy for resistance mutation was
determined during the 55 months. Second, tenofovir had
not been used to treat HBV resistance before 2012 in
China. That is why we alternatively chose combination
therapy with entecavir 1mg plus adefovir 10mg daily to
treat multidrug resistance in month 106.
The mechanism of sequential monotherapy inducing
multidrug resistance has partially been found in recent
years. Coffin and colleagues have detected HBV replica-
tion, drug resistance mutations, and gene diversity in
three different tissues of liver transplant patients with
NA therapy, including explanted liver, peripheral blood
mononuclear cells (PBMCs), and plasma. Their data
showed 100% wild type in plasma, 83% wild type in
PBMCs, but 66% drug resistance in the liver, which was
defined as compartmentalization of HBV variants.
Notably, three patients who experienced lamivudine or
adefovir and complicating resistance mutation were
administered adefovir or tenofovir for rescue therapylasting six to 19 months. The rescue therapy of adefovir or
tenofovir resulted in undetectable HBV DNA and 100%
wild type in plasma, but retained detectable HBV DNA,
covalently closed circular DNA (cccDNA) and resistant
mutations correlating with lamivudine or adefovir in ex-
plant liver. Despite apparent HBV suppression in plasma,
the liver continued to support viral replication and harbor
resistant viruses. On sequence and phylogenetic analysis
of HBV P gene in the liver, the authors further demon-
strated that drug resistance correlated with increased
HBV quasispecies diversity [13]. In the study of Liu et al.,
the authors analyzed the quasispecies complexity of HBV
in plasma of patients with entecavir treatment, in which all
patients were divided into responders and partial
responders. After four weeks, quasispecies complexity in
the responders decreased, while in partial responders it
increased. High quasispecies complexity was correlated
with increased cumulative probability of drug resistance
[14]. Consistent with the studies of Coffin et al. and
Liu et al., initial monotherapy with lamivudine in the
present case induced increased quasispecies complexity,
lamivudine genetic resistance, and virological breakthrough.
The cccDNA of lamivudine-resistant viruses might play a
dual role, as the template for transcription of pregenomic
RNA, and persistence of resistance mutation in the
nucleus of hepatocytes. Subsequently sequential mono-
therapy caused accumulation of resistance mutation by
repeated replication cycle, and eventually resulted in
multidrug resistance. During NA therapy, hepatocytes
harbor multidrug-resistant viruses.
Conclusions
In CHB patients with kidney transplantation or chronic
kidney disease sequential monotherapies with antiviral
agents with low barriers should be avoided, and initial
therapy with entecavir is a better option. Compared with
combination therapy with adefovir plus entecavir, teno-
fovir plus entecavir for kidney transplant patients with
multidrug resistance is safe and effective.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Abbreviations
ADV: adefovir; ALT: alanine aminotransferase; AST: aspartate aminotransferase;
CC: creatinine clearance; cccDNA: covalently closed circular DNA; CHB: chronic
hepatitis B; ETV: entecavir; HBV: hepatitis B virus; IFN: interferon; HBeAg: hepatitis B
e antigen; LdT: telbivudine; LVD: lamivudine; NAs: nucleos(t)ide analogs;
PBMC: peripheral blood mononuclear cell; TDF: tenofovir; ULN: upper limit of
normal; wt: wild type.
Competing interests
The authors declare that they have no competing interests.
Shan et al. Journal of Medical Case Reports 2014, 8:281 Page 6 of 6
http://www.jmedicalcasereports.com/content/8/1/281Authors’ contributions
CS carried out the clinical treatment, follow-up and collection of data, data
analysis and manuscript writing. GQY and PW were responsible for the
conception and design, and final approval of the manuscript. All authors
read and approved the final manuscript.
Acknowledgments
We are grateful for sequence analysis by Dr Mei Sun and Guo Lei Tan in the
Department of Liver Disease Research of the Second Affiliated Hospital,
Southeast University School of Medicine.
Received: 7 February 2014 Accepted: 26 June 2014
Published: 21 August 2014
References
1. Papatheodoridis G, Buti M, Cornberg M, Janssen HL, Mutimer D, Pol S,
Raimondo G, Dusheiko G, Lok A, Marcellin P: EASL clinical practice
guidelines: Management of chronic hepatitis B virus infection.
J Hepatol 2012, 57:167–185.
2. Gish R, Jia JD, Locarnini S, Zoulim F: Selection of chronic hepatitis B
therapy with high barrier to resistance. Lancet Infect Dis 2012, 12:341–353.
3. Vallet-Pichard A, Fontaine H, Mallet V, Pol S: Viral hepatitis in solid organ
transplantation other than liver. J Hepatol 2011, 55:474–482.
4. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK,
Locarnini S, Chronic Hepatitis B Guideline Working Party of the Asian-Pacific
Association for the Study of the Liver: Asian-Pacific consensus statement
on the management of chronic hepatitis B: a 2008 update. Hepatol Int
2008, 2:263–283.
5. Pipili CL, Papatheodoridis GV, Cholongitas EC: Treatment of hepatitis B in
patients with chronic kidney disease. Kidney Int 2013, 84:880–885.
6. Daudé M, Rostaing L, Sauné K, Lavayssière L, Basse G, Esposito L, Guitard J,
Izopet J, Alric L, Kamar N: Tenofovir therapy in hepatitis B virus-positive
solid-organ transplant recipients. Transplantation 2011, 91:916–920.
7. Das P, Vivek V, Ford M, Kingdon E, Holt S: Hepatitis B virus related
membranous glomerulonephritis and proteinuria treated with
lamivudine and tenofovir. BMJ Case Rep 2011.
8. Haque SK, Ariceta G, Batlle D: Proximal renal tubular acidosis: a not so rare
disorder of multiple etiologies. Nephrol Dial Transplant 2012, 27:4273–4287.
9. Gara N, Zhao X, Collins MT, Chong WH, Kleiner DE, Jake Liang T, Ghany MG,
Hoofnagle JH: Renal tubular dysfunction during long-term adefovir or
tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther 2012,
35:1317–1325.
10. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Niño MD,
Izquierdo MC, Poveda J, Sainz-Prestel V, Ortiz-Martin N, Parra-Rodriguez A,
Selgas R, Ruiz-Ortega M, Egido J, Ortiz A: Tenofovir nephrotoxicity 2011
update. AIDS Res Treat 2011, 2011:354908.
11. Mauss S, Berger F, Filmann N, Hueppe D, Henke J, Hegener P, Athmann C,
Schmutz G, Herrmann E: Effect of HBV polymerase inhibitors on renal
function in patients with chronic hepatitis B. J Hepatol 2011, 55:1235–1240.
12. de Vries-Sluijs TE, Reijnders JG, Hansen BE, Zaaijer HL, Prins JM, Pas SD,
Schutten M, Hoepelman AI, Richter C, Mulder JW, de Man RA, Janssen HL,
van der Ende ME: Long-term therapy with tenofovir is effective for
patients co-infected with human immunodeficiency virus and hepatitis
B virus. Gastroenterology 2010, 139:1934–1941.
13. Coffin CS, Mulrooney-Cousins PM, Peters MG, van Marle G, Roberts JP,
Michalak TI, Terrault NA: Molecular characterization of intrahepatic and
extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive
antiviral therapy. J Viral Hepat 2011, 18:415–423.
14. Liu F, Chen L, Yu DM, Deng L, Chen R, Jiang Y, Chen L, Huang SY, Yu JL,
Gong QM, Zhang XX: Evolutionary patterns of hepatitis B virus
quasispecies under different selective pressures: correlation with
antiviral efficacy. Gut 2011, 60:1269–1277.
doi:10.1186/1752-1947-8-281
Cite this article as: Shan et al.: Efficacy and safety of tenofovir in a
kidney transplant patient with chronic hepatitis B and nucleos(t)ide
multidrug resistance: a case report. Journal of Medical Case Reports
2014 8:281.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
